Financing will support development of first-in-class CNS-selective sodium channel modulatorsCHARLOTTESVILLE, VA / ACCESSWIRE / October 26, 2021 / GenEp, Inc., a biotechnology company developing therapies
Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies
Financing will support development of novel IL-2 treatments for various diseases
CHARLOTTESVILLE, Va., Jan. 19, 2021 /PRNewswire/ Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technology s GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., management and others. Slate is a pre-clinical biotechnology company developing paradigm shifting IL-2 compounds based on research conducted at the University of Virginia School of Medicine. IL233, Slate s lead candidate, is a first in class drug that induces persistent remission in animal models of autoimmune and inflammatory diseases.